Examnitaion of the primary prevention effect of BPSD in the additional dosage of the mementine hydrochloride for the Alzheimer's disease

Examnitaion of the primary prevention effect of BPSD in the additional dosage of the mementine hydrochloride for the Alzheimer's disease - the study of the additional dosage of the mementine hydrochloride

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012340

Enrollment

Registered

2013-11-22

Start date

2013-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer&#39

Interventions

acetylcholinesterase inhibitor acetylcholinesterase inhibitor and memantine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. the moderate to severe Alzheimer's desease patients 2. the patients who have no BPSD and the treatment of acetylcholinesterase inhibitor for more than 9 months 3. the patients who meat DSM-4 and NINCDS-ADRDA the criteria for Alzheimer's desease

Exclusion criteria

Exclusion criteria: 1.dementia patients except Alzheimer's desease 2.the patients who have severe mental desorder 3.the patients having the serious disease including the malignant neoplasm 4.the patients with a history of the hypersensitivity for memantine hydrochloride 5.the patients who corresponds to a contraindication in an attached document 6.In addition, the case that a principal investigator or subinvestigator judged to be inappropriate

Design outcomes

Primary

Measure	Time frame
BPSD	—

Secondary

Measure	Time frame
Cognitive function Safety	—

Countries

Japan

Contacts

Public ContactHiroyuki Shimada. M.D ., PhD.

Osaka City University Graduate school of Medicine Geriatric Medicine

h.shimada@med.osaka-cu.ac.jp06-6645-3889

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

Examnitaion of the primary prevention effect of BPSD in the additional dosage of the mementine hydrochloride for the Alzheimer&#39;s disease